Comparative genomic hybridization findings and Southern blotting for human T-lymphotropic virus type 1 provirus integration at different sites, and sequential analysis
| Patient no. . | Types of difference . | HTLV-1 integration . | CGH findings . | |
|---|---|---|---|---|
| Different sites . | First/second sample . | First sample . | Second sample . | |
| 29 | PB/LN | Identical | +1q, +3, −10p, +11q23, +18q, +Y | +1q, +3, −10p, +11q22-q23, +18q12-qter |
| 38 | PB/LN | Identical | +3p,−6q26-qter, −13q32-qter | +3p, −6p22-pter,+6q13-q24, −13q32-qter |
| 43 | A/S | Identical | +22, +Xq, −Y | −3q27, +16p, −16q, −Y |
| 49 | PB/LN | Identical | No gains or losses | 1p35-pter(+) |
| Sequential analysis | ||||
| 11 | Ch/Cr | Identical | +14q22-qter | +14q22-qter |
| 23 | Ch/Cr | Distinct | +5 | +1p36-pter,+1q, −3q21-25, +4q24-q28,−10, −13q32-qter, −16,+18, +20 |
| 57 | Ch/Cr | Identical | +7q31-qter | −4q21-q22, +7q22-qter, +9p22-pter, +14q24-qter,−X |
| 62 | Ch/Cr | Distinct | −7p22,−19p13.3 | +2p24-pter,−18q22-qter |
| 63 | Ch/Cr | Identical | +19p13-pter | −9q22, +19p13-pter |
| 64 | Ch/Cr | Identical | +3p, −4q21, −6q27-qter, +7q32-qter, −9q22, −18p, +18q | +3p, −4q21-q22, −6q27-qter, +7q32-qter, −9q21-q22, −18p, +18q |
| 2 | AO/R | Identical | +1q,+2q33-q34, +3q24-qter, +4q24-q31.3, +7q22-qter, −12p12-pter, +14q31-qter, +20q11-q13, −Y | +1q, +3q24-qter, +4q24-q32, +7q22-qter, −12p12-pter, +14q24-qter,+19p, −Y |
| 6 | AO/R | Identical | +1q,+2, +4q31-qter, +7q21-qter, −8p22-pter,+9q32-qter, +10q21-qter, +14q21-qter,−15q26-qter, +17p11.2-q21, +18p11.2-qter,+19p | +1q, +4q32-qter, +7q21-qter, −8p22-pter,+8q24-qter, +12q13-qter, +14q21-qter, +17p11.2-q21, −18p11.2-pter, +18q12-q22 |
| 16 | AO/R | Identical | +3, −4q32-qter, +7q21-q31, +9q, −10p,−13q31-qter, +14q31-qter, −17p, +18q22-qter, +21 | +3q, −4q32-qter, +7q21-q31, +9q, −10p, +11p15-pter,−11q24-qter, +14q31-qter, −17p, +18q22-qter, +21 |
| 20 | AO/R | Identical | +3q, +4q25-qter, −6q12-q16, −6q26-qter, +10p12-pter, +10q11.2-q23, −10q24-qter, −16q11.2-q21 | +3p21-qter, −3p25-pter, +4q25-qter, −5p13-p15.2, −6q12-q16, −6q26-qter,−10p12-q11, −10q24-qter, +14q31-qter, −16q11.2-q21, +18q21-q22, −18q22-qter,−Y |
| 27 | AO/R | Identical | +1q21-q41,+3p14-pter, −7q31-q32,−13q22-qter, +18 | No gains or losses |
| 30 | AO/R | Identical | +1q, +4pter-q28,+7q22-qter, −9q22, −10q25-qter,+11q22-qter, +14q31-qter | +14q31-qter |
| 58 | AO/R | Identical | +1q12-q25, +3, +8, +11q, +14q24-qter, −18p | +1q12-q25, +8, +11q, +14q24-qter,+16p, −18p |
| Patient no. . | Types of difference . | HTLV-1 integration . | CGH findings . | |
|---|---|---|---|---|
| Different sites . | First/second sample . | First sample . | Second sample . | |
| 29 | PB/LN | Identical | +1q, +3, −10p, +11q23, +18q, +Y | +1q, +3, −10p, +11q22-q23, +18q12-qter |
| 38 | PB/LN | Identical | +3p,−6q26-qter, −13q32-qter | +3p, −6p22-pter,+6q13-q24, −13q32-qter |
| 43 | A/S | Identical | +22, +Xq, −Y | −3q27, +16p, −16q, −Y |
| 49 | PB/LN | Identical | No gains or losses | 1p35-pter(+) |
| Sequential analysis | ||||
| 11 | Ch/Cr | Identical | +14q22-qter | +14q22-qter |
| 23 | Ch/Cr | Distinct | +5 | +1p36-pter,+1q, −3q21-25, +4q24-q28,−10, −13q32-qter, −16,+18, +20 |
| 57 | Ch/Cr | Identical | +7q31-qter | −4q21-q22, +7q22-qter, +9p22-pter, +14q24-qter,−X |
| 62 | Ch/Cr | Distinct | −7p22,−19p13.3 | +2p24-pter,−18q22-qter |
| 63 | Ch/Cr | Identical | +19p13-pter | −9q22, +19p13-pter |
| 64 | Ch/Cr | Identical | +3p, −4q21, −6q27-qter, +7q32-qter, −9q22, −18p, +18q | +3p, −4q21-q22, −6q27-qter, +7q32-qter, −9q21-q22, −18p, +18q |
| 2 | AO/R | Identical | +1q,+2q33-q34, +3q24-qter, +4q24-q31.3, +7q22-qter, −12p12-pter, +14q31-qter, +20q11-q13, −Y | +1q, +3q24-qter, +4q24-q32, +7q22-qter, −12p12-pter, +14q24-qter,+19p, −Y |
| 6 | AO/R | Identical | +1q,+2, +4q31-qter, +7q21-qter, −8p22-pter,+9q32-qter, +10q21-qter, +14q21-qter,−15q26-qter, +17p11.2-q21, +18p11.2-qter,+19p | +1q, +4q32-qter, +7q21-qter, −8p22-pter,+8q24-qter, +12q13-qter, +14q21-qter, +17p11.2-q21, −18p11.2-pter, +18q12-q22 |
| 16 | AO/R | Identical | +3, −4q32-qter, +7q21-q31, +9q, −10p,−13q31-qter, +14q31-qter, −17p, +18q22-qter, +21 | +3q, −4q32-qter, +7q21-q31, +9q, −10p, +11p15-pter,−11q24-qter, +14q31-qter, −17p, +18q22-qter, +21 |
| 20 | AO/R | Identical | +3q, +4q25-qter, −6q12-q16, −6q26-qter, +10p12-pter, +10q11.2-q23, −10q24-qter, −16q11.2-q21 | +3p21-qter, −3p25-pter, +4q25-qter, −5p13-p15.2, −6q12-q16, −6q26-qter,−10p12-q11, −10q24-qter, +14q31-qter, −16q11.2-q21, +18q21-q22, −18q22-qter,−Y |
| 27 | AO/R | Identical | +1q21-q41,+3p14-pter, −7q31-q32,−13q22-qter, +18 | No gains or losses |
| 30 | AO/R | Identical | +1q, +4pter-q28,+7q22-qter, −9q22, −10q25-qter,+11q22-qter, +14q31-qter | +14q31-qter |
| 58 | AO/R | Identical | +1q12-q25, +3, +8, +11q, +14q24-qter, −18p | +1q12-q25, +8, +11q, +14q24-qter,+16p, −18p |
Difference in the paired samples are underlined.
PB indicates peripheral blood; LN, lymph node; A, ascites; S, skin; Ch, chronic; Cr, crisis; AO, acute onset; R, relapse; HTLV-1, human T-lymphotropic virus type 1; and CGH, comparative genomic hybridization.